Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline
resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial …

Background Patients with borderline resectable pancreatic ductal adenocarcinoma have
relatively low resection rates and poor survival despite the use of adjuvant chemotherapy …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …

PURPOSE Preoperative chemoradiotherapy may improve the radical resection rate for
resectable or borderline resectable pancreatic cancer, but the overall benefit is unproven …

Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …